Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 3Sarcoma 1Endocrine 1

Conditions

Paraganglioma 1

Interventions

Everolimus 23pasireotide 14lutetium Lu 177 dotatate 10Octreotide 10lanreotide 9surufatinib 8Carboplatin 8Paclitaxel 7pembrolizumab 5amino-acid, glucose, and electrolyte solution 5Thyrotropin Alfa 5Sunitinib 5Nivolumab 5Injections 53-Iodobenzylguanidine 5relacorilant 4fosbretabulin 4Temozolomide 4Fulvestrant 4Etoposide 4Data Collection 4Cisplatin 4vandetanib 3selpercatinib 3dabrafenib 3anlotinib 3Mifepristone 3Lutetium-177 3Lutetium 3Irinotecan 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × ONC206 × Endocrine × Clear all
NCT07282587 2026-02-27

Study of ONC206 (JZP3507) in Advanced Pheochromocytoma and Paraganglioma

Jazz Pharmaceuticals

Phase 2 Recruiting
90 enrolled
CNSEndocrine

Paraganglioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡